Skip to main content
Synbiotic SE logo

Synbiotic SE — Investor Relations & Filings

Ticker · SBX ISIN · DE000A3E5A59 LEI · 48510041U2G1IWA3R418 F Manufacturing
Open in API
Filings indexed 140 across all filing types
Latest filing 2024-04-25 Regulatory Filings
Country DE Germany
Listing F SBX

About Synbiotic SE

https://www.synbiotic.com/

Synbiotic SE is a European corporate group focused on the medical cannabis and industrial hemp markets. The company operates a platform model, making strategic investments in ventures across these sectors to create synergies. Its business is vertically integrated, covering the entire value chain from cultivation, research, and development to the production, sales, and distribution of hemp- and cannabinoid-based products. The company's portfolio includes a wide range of high-quality hemp, CBD, and cannabis products, leveraging its expertise across the full supply chain from seed to shelf.

Recent filings

Filing Released Lang Actions
1.6 million euros for Hanf Farm: Federal Ministry for Economic Affairs and Climate Protection funds bio-economy project (news with additional features)
Regulatory Filings Classification · 100% confidence The document is a news release distributed via EQS News, announcing that the Federal Ministry for Economic Affairs and Climate Protection (BMWK) is funding a project by Hanf Farm GmbH (a subsidiary of SYNBIOTIC SE) with 1.6 million euros for bio-economy development. The content focuses on a specific government funding award, which relates to capital/financing activities, although it is presented as a news announcement. Since the core event is securing funding, the most appropriate category is 'Capital/Financing Update' (CAP). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a management discussion (MDA). It is a specific announcement about securing funds, fitting best under CAP.
2024-04-25 English
SYNBIOTIC acquires Ilesol: Enormous competitive advantages through cannabinoid extracts and isolates from own production
M&A Activity Classification · 100% confidence The document is a news release dated April 23, 2024, announcing that SYNBIOTIC SE has acquired Ilesol Pharmaceuticals. The text explicitly uses the keyword 'Takeover' and details a significant corporate transaction (M&A activity). This fits the definition of M&A Activity (TAR). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it describes a specific strategic event.
2024-04-23 English
SynBiotic SE schliet Einbringungsvertrag uber den Erwerb aller Anteile an der Ilesol Pharmaceuticals d.o.o. (Kroatien)
Share Issue/Capital Change Classification · 99% confidence The document is an 'Ad-hoc' announcement dated April 19, 2024, explicitly stating it is an 'Insiderinformation gem. Artikel 17 der Verordnung (EU) Nr. 596/2014' (Insider Information pursuant to Article 17 of Regulation (EU) No. 596/2014). The content details the signing of an agreement to acquire all shares of another company (Ilesol Pharmaceuticals d.o.o.) through a capital increase and share transfer. This type of announcement, concerning a significant corporate transaction like an acquisition or takeover proposal, falls under the category of M&A Activity (TAR). Although it is a regulatory disclosure, 'TAR' is more specific than the general 'RNS' fallback.
2024-04-19 German
SYNBIOTIC SE: Nach Teil-Legalisierung: Bushdoctor meldet starkes Auftragsplus aus Deutschland
Earnings Release Classification · 99% confidence The document is a press release dated April 12, 2024, issued by SYNBIOTIC SE via EQS News. It details positive business developments (strong order increase for subsidiary Bushdoctor) following the partial legalization of cannabis in Germany and outlines strategic marketing initiatives. This type of announcement, focusing on immediate business updates, operational changes, and market reaction, is characteristic of an Earnings Release (ER) or a general news announcement. Since it is not a full financial report (like 10-K or IR), nor a formal regulatory filing like a Director's Dealing or Major Shareholding notification, and it reports on recent performance/outlook, it best fits the Earnings Release (ER) category, which covers initial announcements of periodical results/highlights. Given the context of a news release about business performance following a regulatory change, ER is the most appropriate fit among the specific financial filing types. If it were purely administrative or non-financial news, RNS would be considered, but this contains performance commentary. Q4 2023
2024-04-12 German
SynBiotic SE: Deutschlands fuhrende Cannabis-Unternehmensgruppe nimmt Stellung zur Bundesratsentscheidung zum Cannabisgesetz
Regulatory Filings Classification · 100% confidence The document is a press release issued via EQS News on March 22, 2024, titled "SynBiotic SE: Deutschlands führende Cannabis-Unternehmensgruppe nimmt Stellung zur Bundesratsentscheidung zum Cannabisgesetz" (SynBiotic SE: Germany's leading cannabis group comments on the Federal Council's decision on the Cannabis Act). It contains commentary from management (Daniel Kruse and Emilio Ropero) regarding a recent political/regulatory decision (the Cannabisgesetz). It is not a formal financial report (like 10-K or IR), an earnings release (ER), or a transcript (CT). Since it is a general announcement concerning a legal/regulatory development and provides company commentary, it fits best under the general Regulatory Filings (RNS) category, as it is a news release distributed through a regulatory news service (EQS) that doesn't fit the more specific categories like DIV, DIRS, or ER. Given the content is a reaction to a legal/political event, RNS is the most appropriate general classification for this type of corporate news release.
2024-03-22 German
SynBiotic SE: Frank Otto, Granting of 86,465 subscription rights as part of the rights issue of a 6% convertible bond March 2024/2025.
Share Issue/Capital Change Classification · 99% confidence The document explicitly states 'Directors’ Dealings' in the title and details a transaction involving a member of the administrative body (Frank Otto). The structure follows the standard format for notifying transactions by persons discharging managerial responsibilities (PDMRs). This directly corresponds to the definition of Director's Dealing (DIRS). Although the transaction involves subscription rights related to a convertible bond, the core nature of the filing is the disclosure of an insider's transaction.
2024-03-19 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.